Bone cancers
- PMID: 8000997
- DOI: 10.1002/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v
Bone cancers
Abstract
Background: Frequency distribution data for primary bone sarcomas have long been used to provide clues to the diagnosis of bone cancers after their identification in radiographs. Age and skeletal site are often helpful, in addition to specific radiographic features, in narrowing down the probable histologic categories of bone neoplasms before biopsy.
Methods: Data on 2627 histologically confirmed primary malignant tumors of bone, as collected by the SEER program during the period 1973-1987, were analyzed by age, sex, race, and anatomical site.
Results: Osteosarcoma was the most frequently diagnosed primary sarcoma of bone (35.1%), followed by chondrosarcoma (25.8%), Ewing's sarcoma (16.0%), chordoma (8.4%), and malignant fibrous histiocytoma, including fibrosarcoma (5.6%). The most frequently diagnosed sarcoma of bone in persons younger than age 20 was osteosarcoma, followed by Ewing's sarcoma. Chondrosarcoma was the most frequently diagnosed bone tumor in the population older than age 50. The overall 5-year relative survival rates were as follows: osteosarcoma, 41.0%; chondrosarcoma, 72.7%; Ewing's sarcoma, 41.2%; chordoma, 63.8%; and malignant fibrous histiocytoma, 42.9%. There was an improvement in the survival rates during the period 1973-1987 for patients with chordoma and for white female patients with Ewing's sarcoma. Ewing's sarcoma and chordoma occurred almost exclusively in the white population.
Conclusions: SEER data provide a unique opportunity to evaluate the incidence and survival rates of bone sarcomas, which are uncommon but highly lethal tumors. The findings from this analysis provide information useful in the diagnosis of these cancers.
Similar articles
-
Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.J Neurosurg Spine. 2011 Feb;14(2):143-50. doi: 10.3171/2010.10.SPINE10189. Epub 2010 Dec 24. J Neurosurg Spine. 2011. PMID: 21184634
-
Primary malignant bone tumours in Western Australia, 1972-1996.Pathology. 2005 Aug;37(4):278-83. doi: 10.1080/00313020500168737. Pathology. 2005. PMID: 16194825
-
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report.Clin Orthop Relat Res. 2007 Jun;459:40-7. doi: 10.1097/BLO.0b013e318059b8c9. Clin Orthop Relat Res. 2007. PMID: 17414166
-
Malignant bone tumors.Instr Course Lect. 2008;57:673-88. Instr Course Lect. 2008. PMID: 18399615 Review.
-
Lymphatic dissemination of bone and soft tissue sarcomas: a lymphographic investigation.Acta Radiol Suppl. 1976;349:1-84. Acta Radiol Suppl. 1976. PMID: 206099 Review.
Cited by
-
Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.J Bone Oncol. 2023 Nov 3;43:100511. doi: 10.1016/j.jbo.2023.100511. eCollection 2023 Dec. J Bone Oncol. 2023. PMID: 38058514 Free PMC article. Review.
-
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice.Oncol Rep. 2020 Jan;43(1):169-176. doi: 10.3892/or.2019.7420. Epub 2019 Nov 28. Oncol Rep. 2020. PMID: 31789402 Free PMC article.
-
HACE1 is a potential tumor suppressor in osteosarcoma.Cell Death Dis. 2019 Jan 8;10(1):21. doi: 10.1038/s41419-018-1276-4. Cell Death Dis. 2019. PMID: 30622235 Free PMC article.
-
Barium Titanate Nanoparticles: Highly Cytocompatible Dispersions in Glycol-chitosan and Doxorubicin Complexes for Cancer Therapy.Nanoscale Res Lett. 2010 May 9;5(7):1093-101. doi: 10.1007/s11671-010-9607-0. Nanoscale Res Lett. 2010. PMID: 20596329 Free PMC article.
-
Growing Pains: The Need for Engineered Platforms to Study Growth Plate Biology.Adv Healthc Mater. 2022 Oct;11(19):e2200471. doi: 10.1002/adhm.202200471. Epub 2022 Aug 15. Adv Healthc Mater. 2022. PMID: 35905390 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical